The dry powder inhalation of antibiotics for the treatment of lung infections has attracted drastically increasing attention as it offers rapid local therapy at lower doses and minimal side effects.In this study,aztre...The dry powder inhalation of antibiotics for the treatment of lung infections has attracted drastically increasing attention as it offers rapid local therapy at lower doses and minimal side effects.In this study,aztreonam(AZT)was used as the model antibiotic and spraydried to prepare powders for inhalation.Amino acids of glycine(GLY),histidine(HIS)and leucine(LEU)were used as excipients to modify the spray-dried particles.It was demonstrated that the GLY-AZT spray-dried powders formed huge agglomerates with the size of 144.51μm,which made it very difficult to be delivered to the lungs(FPF:0.29%w/w only).In comparison with the AZT spray-dried powders,HIS-modified spray-dried powders showed increased compressibility,indicating larger distance and less cohesion between particles;while the LEU-modified spray-dried particles showed a hollow structure with significantly decreased densities.The fine particle fraction for HIS-and LEU-modified powders was 51.4%w/w and 61.7%w/w,respectively,and both were significantly increased(one-way ANOVA,Duncan’s test,P<0.05)compared to that of AZT spray-dried powders(45.4%w/w),showing a great potential to be applied in clinic.展开更多
A 61-year-old female with past medical history of maculopapular rash reaction to ciprofloxacin and amoxicillin being treated for diverticulitis develops the same rash with administration of piperacillin/tazobactam and...A 61-year-old female with past medical history of maculopapular rash reaction to ciprofloxacin and amoxicillin being treated for diverticulitis develops the same rash with administration of piperacillin/tazobactam and aztreonam. A diffuse maculopapular rash developed after the administration of piperacillin. It resolved with discontinuation of the drug and the patient was switched to aztreonam and a very similar rash developed subsequently. In a review of the literature, there are no documented cases of a patient with an allergy to both aztreonam and piperacillin/tazobactam despite in vivo cross-reactivity. Unfortunately, there are no standardized allergy tests for aztreonam or piperacillin. This case, however, does offer the possibility that aztreonam may not always be the right alternative to persons with beta-lactam antibiotic allergies.展开更多
基金support from Natural Science Foundation of Jiangsu Province(BK2011295)Youth Fund of Soochow University(SDY2011A21)。
文摘The dry powder inhalation of antibiotics for the treatment of lung infections has attracted drastically increasing attention as it offers rapid local therapy at lower doses and minimal side effects.In this study,aztreonam(AZT)was used as the model antibiotic and spraydried to prepare powders for inhalation.Amino acids of glycine(GLY),histidine(HIS)and leucine(LEU)were used as excipients to modify the spray-dried particles.It was demonstrated that the GLY-AZT spray-dried powders formed huge agglomerates with the size of 144.51μm,which made it very difficult to be delivered to the lungs(FPF:0.29%w/w only).In comparison with the AZT spray-dried powders,HIS-modified spray-dried powders showed increased compressibility,indicating larger distance and less cohesion between particles;while the LEU-modified spray-dried particles showed a hollow structure with significantly decreased densities.The fine particle fraction for HIS-and LEU-modified powders was 51.4%w/w and 61.7%w/w,respectively,and both were significantly increased(one-way ANOVA,Duncan’s test,P<0.05)compared to that of AZT spray-dried powders(45.4%w/w),showing a great potential to be applied in clinic.
文摘A 61-year-old female with past medical history of maculopapular rash reaction to ciprofloxacin and amoxicillin being treated for diverticulitis develops the same rash with administration of piperacillin/tazobactam and aztreonam. A diffuse maculopapular rash developed after the administration of piperacillin. It resolved with discontinuation of the drug and the patient was switched to aztreonam and a very similar rash developed subsequently. In a review of the literature, there are no documented cases of a patient with an allergy to both aztreonam and piperacillin/tazobactam despite in vivo cross-reactivity. Unfortunately, there are no standardized allergy tests for aztreonam or piperacillin. This case, however, does offer the possibility that aztreonam may not always be the right alternative to persons with beta-lactam antibiotic allergies.
